Brain Advance Access originally published online on June 25, 2008
Brain 2008 131(7):1845-1853; doi:10.1093/brain/awn107
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease
1Turku PET Centre, University of Turku, Turku, 2Department of Neurology, Helsinki University Central Hospital, Helsinki, 3Department of Psychology, Åbo Akademi University, Turku, 4Department of Pathology, University and University Hospital of Helsinki, Helsinki, 5Department of Neurology, Tampere University Central Hospital, Tampere, 6Department of Geriatrics, University of Turku, Turku, 7Department of Pathology, University of Uppsala, Sweden and 8Departments of Pathology and Forensic Medicine, University of Turku, Finland
Correspondence to: Juha O. Rinne, MD, PhD, Turku PET Centre, University of Turku, PO Box 52, 20521 Turku, Finland E-mail: juha.rinne{at}tyks.fi
Variant Alzheimer's disease (VarAD) with spastic paraparesis and presenile dementia is associated with certain mutations of the presenilin 1 (PS-1) gene, particularly those leading to deletion of exon 9 (PS-1
E9). VarAD is neuropathologically characterized by the presence of unusually large, Aβ42 positive, non-cored ‘cotton wool’ plaques (CWPs), also devoid of dystrophic neurites. The aim of the present study was to find out whether [11C]PIB would show increased uptake and serve as an in vivo biomarker of amyloid accumulation in VarAD. A further aim was to assess the correspondence of the [11C]PIB binding to the amount and type of Aβ deposits in another group of deceased VarAD patients’ brains. We studied four patients with VarAD and eight healthy controls with PET using [11C]PIB as tracer. Parametric images were computed by calculating the region-to-cerebellum and region-to-pons ratio in each voxel over 60–90 min. Group differences in [11C]PIB uptake were analysed with automated region-of-interest (ROI) analysis. [11C]PIB uptake was compared to the immunohistochemically demonstrated deposition of Aβ in the brains of another group of four deceased VarAD patients. Patients with VarAD had significantly higher [11C] PIB uptake than the control group in the striatum (caudate nucleus and putamen), anterior and posterior cingulate gyrus, occipital cortex and thalamus. In the caudate and putamen [11C]PIB uptake, expressed as region-to-cerebellum ratio, was on the average 43% greater than the mean of the control group. The increases in the anterior (28%) and posterior (27%) cingulate gyrus, occipital cortex (21%) and thalamus (14%) were smaller. All VarAD patients showed this similar topographical pattern of increased [11C]PIB uptake. The results were essentially similar when the uptake was expressed as region-to-pons ratios. [11C]PIB imaging shows increased uptake in patients with VarAD especially in the striatum, and it can be used to detect amyloid accumulation in vivo in these patients. The pattern of increased [11C]PIB uptake is different from that described in sporadic Alzheimer's disease and resembles that seen in Alzheimer's disease patients with certain presenilin-1 mutations or amyloid precursor protein gene duplication showing predominantly striatal increase in [11C]PIB uptake.
Key Words: variant Alzheimer's disease; PET; PIB
Abbreviations: AβPP, β-amyloid precursor protein; CWPs, cotton wool plaques; FAD, Familial Alzheimer's disease; GP, Globus pallidus; MMSE, Mini-Mental State Examination; PET, positron emission tomography; PS-1, presenilin 1; ROI, region-of-interest; SPM, Parametric Mapping version; VarAD, Variant Alzheimer's disease
Received December 19, 2007. Revised April 14, 2008. Accepted May 9, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in Brain:
- Editorial
- Alastair Compston
Brain 2008 131: 1675-1676.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  V. L. Villemagne, S. Ataka, T. Mizuno, W. S. Brooks, Y. Wada, M. Kondo, G. Jones, Y. Watanabe, R. Mulligan, M. Nakagawa, et al. High Striatal Amyloid {beta}-Peptide Deposition Across Different Autosomal Alzheimer Disease Mutation Types Arch Neurol, December 1, 2009; 66(12): 1537 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Okello, J. Koivunen, P. Edison, H. A. Archer, F. E. Turkheimer, K. Nagren, R. Bullock, Z. Walker, A. Kennedy, N. C. Fox, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study Neurology, September 8, 2009; 73(10): 754 - 760. [Abstract] [Full Text] [PDF]
|
|